Cargando…

Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease

Detalles Bibliográficos
Autores principales:	Lin, Q, Fang, B, Huang, H, Yu, F, Chai, X, Zhang, Y, Zhou, J, Xia, Q, Li, Y, Song, Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382655/ https://www.ncbi.nlm.nih.gov/pubmed/25794134 http://dx.doi.org/10.1038/bcj.2015.12

Ejemplares similares

Efficacy of Thalidomide for Recurrent Gastrointestinal Bleeding due to angiodysplasias in a Hemodialysis Patient
por: Tamzaourte, M., et al.
Publicado: (2017)

Multicentric Castleman's disease: Closest mimic of lymphoma on FDG PET/CT
por: Puranik, Ameya D, et al.
Publicado: (2013)

A Rare Variant of Idiopathic Multicentric Castleman Disease: TAFRO Syndrome
por: Ük, Ece, et al.
Publicado: (2022)

Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report
por: Yuan, Zhen-gang, et al.
Publicado: (2009)

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
por: Hulin, Cyrille, et al.
Publicado: (2021)

Castleman Disease: Diagnosis on Cytology
por: Singh, Suneet, et al.
Publicado: (2023)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
por: Castro, T.B.M., et al.
Publicado: (2016)

Multicentric Castleman's disease: “A rare entity that mimics malignancy”
por: Acharya, Vishak K, et al.
Publicado: (2016)

TdT+ T-Lymphoblastic Proliferation in Castleman Disease
por: Woo, Chang Gok, et al.
Publicado: (2015)

Alveolar Hemorrhage in Idiopathic Multicentric Castleman’s Disease
por: Huang, Lingtong, et al.
Publicado: (2023)

The Recrudescence of Quarantine
Publicado: (1898)

Radiation therapy in the treatment of unicentric Castleman's disease
por: Miranda, Fabiana Accioli, et al.
Publicado: (2013)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen
por: Jacobus, S J, et al.
Publicado: (2016)

Idiopathic multicentric castleman’s disease mimicking immunoglobulin G4-related disease responding well to Bortezomib: a case report
por: Peng, Qian, et al.
Publicado: (2023)

Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease
por: Nishikori, Asami, et al.
Publicado: (2022)

The Role of Radiotherapy Among the Therapeutic Options for Castleman’s Disease
por: Karaca, Feryal, et al.
Publicado: (2014)

Pre- and post-therapy (18)F-FDG PET/CT of a patient affected by non-HIV multicentric IgG4-related Castleman disease
por: Savelli, Giordano, et al.
Publicado: (2015)

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
por: Del Fabro, V., et al.
Publicado: (2023)

A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma
por: Becker, P S, et al.
Publicado: (2016)

The Recrudescence Theory of Plague
Publicado: (1904)

The Recrudescence of Mrs. Eddy
Publicado: (1906)

HIV-associated multicentric Castleman's disease
por: Naime, Fauzia de Fátima, et al.
Publicado: (2012)

Multicentric Castleman disease and the evolution of the concept
por: Zhou, Ting, et al.
Publicado: (2021)

Castleman's disease: A rare differential diagnosis for retroperitoneal tumors
por: Shringarpure, Sanish, et al.
Publicado: (2010)

A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor
por: Hattori, Y, et al.
Publicado: (2013)

Comment on: ‘Vitamin D supplements and cancer incidence and mortality: a meta-analysis'
por: Jiang, D-Q, et al.
Publicado: (2015)

A case of granuloma faciale successfully treated with oral prednisone, tranilast and thalidomide
por: Yuan, Chunyu, et al.
Publicado: (2018)

An unusual complication of bortezomib therapy: Acute pancreatitis
por: Gupta, H., et al.
Publicado: (2014)

Bortezomib-Based Regimens and Plasma Cell Leukemia
por: Bolaman, Ali Zahit
Publicado: (2021)

Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
por: Kang, Wonseok, et al.
Publicado: (2010)

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
por: Garcia, M Kay, et al.
Publicado: (2014)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Renal pathological changes after successful treatment of LCDD using cyclophosphamide, thalidomide, and dexamethasone
por: Wang, Di, et al.
Publicado: (2021)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Multicentric Castleman's disease: a case report
por: Menezes, Brian F, et al.
Publicado: (2007)

Multicentric Castleman's disease: Report of three cases
por: Guazzaroni, M., et al.
Publicado: (2018)

Multicentric Castleman disease with TAFRO syndrome and Sjögren's
por: Li, Zi Ying, et al.
Publicado: (2019)

Updates on the diagnosis and management of multicentric Castleman disease
por: Wu, Ya-Ju, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r19u1n4i558vge0tsn0jpruofo